Cabozantinib in genitourinary malignancies.
Publication
, Journal Article
Zhang, T; Park, SE; Hong, C; George, DJ
Published in: Future Oncol
April 2017
Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. These signaling pathways have been shown to be important in genitourinary malignancies. Along its clinical development, it has shown most activity in advanced renal cell carcinoma; the METEOR study compared cabozantinib to everolimus and showed clinically and statistically significant improvements in both progression-free survival and overall survival. Herein, we review the development of cabozantinib in the genitourinary malignancies of renal cell carcinoma, prostate adenocarcinoma and urothelial carcinoma.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Future Oncol
DOI
EISSN
1744-8301
Publication Date
April 2017
Volume
13
Issue
8
Start / End Page
755 / 765
Location
England
Related Subject Headings
- Urogenital Neoplasms
- Treatment Outcome
- Pyridines
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Grading
- Humans
- Clinical Trials, Phase III as Topic
- Clinical Trials, Phase II as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Zhang, T., Park, S. E., Hong, C., & George, D. J. (2017). Cabozantinib in genitourinary malignancies. Future Oncol, 13(8), 755–765. https://doi.org/10.2217/fon-2016-0358
Zhang, Tian, Se Eun Park, Cierra Hong, and Daniel J. George. “Cabozantinib in genitourinary malignancies.” Future Oncol 13, no. 8 (April 2017): 755–65. https://doi.org/10.2217/fon-2016-0358.
Zhang T, Park SE, Hong C, George DJ. Cabozantinib in genitourinary malignancies. Future Oncol. 2017 Apr;13(8):755–65.
Zhang, Tian, et al. “Cabozantinib in genitourinary malignancies.” Future Oncol, vol. 13, no. 8, Apr. 2017, pp. 755–65. Pubmed, doi:10.2217/fon-2016-0358.
Zhang T, Park SE, Hong C, George DJ. Cabozantinib in genitourinary malignancies. Future Oncol. 2017 Apr;13(8):755–765.
Published In
Future Oncol
DOI
EISSN
1744-8301
Publication Date
April 2017
Volume
13
Issue
8
Start / End Page
755 / 765
Location
England
Related Subject Headings
- Urogenital Neoplasms
- Treatment Outcome
- Pyridines
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Grading
- Humans
- Clinical Trials, Phase III as Topic
- Clinical Trials, Phase II as Topic